Table 1.
Study Characteristics of Included Publications (n=74 Primary Publications)
| Study | Study Design | Device | Sample Size | Follow-Up Duration |
|---|---|---|---|---|
| Clinical outcomes | ||||
| Ahmed 2020a24 | RCT | Hydrus, iStent | 152 patients (152 eyes) | 12 months |
| Arriola-Villalobos 201259 | Prospective interventional case series | iStent | 19 patients | Mean (SD): 53.68 (9.26) months |
| Chansangpetch 202060 | Retrospective study | iStent | 89 patients (104 eyes) | 12 months |
| ElMallah 202061 | Retrospective study | KDB | 35 patients (42 eyes) | 12 months |
| Falkenberry 202013 | RCT | KDB, iStent | 164 patients (164 eyes) | 12 months |
| Fea 201711 | Prospective interventional case series | SLT, Hydrus | 56 patients (56 eyes) | 12 months |
| Ferguson 2016a62 | Retrospective consecutive case series | iStent | 42 eyes | 24 months |
| Ferguson 2016b63 | Retrospective consecutive case series | iStent | 350 eyes | 24 months |
| Ferguson 2020a64 | Retrospective consecutive case series | iStent | 67 patients (117 eyes) | 60 months |
| Ferguson 2020b65 | Retrospective consecutive case series | iStent | 411 eyes | 72 months |
| Gallardo 202115 | Prospective, multicentre study | OMNI | 137 patients (137 eyes) | 6 months |
| Garg 201828 | Cross-sectional data analysis of a prospective cohort study | NA | 44 patients (88 eyes) | NA (cross-sectional study) |
| Gazzard 20195 | RCT | Manufacturer details not provided | 718 patients (1235 eyes) | 36 months |
| Gillmann 202066 | Prospective interventional study | iStent inject | 42 patients (54 eyes) | 12 months |
| Gonnermann 201767 | Retrospective study | Trabectome, iStent inject | 27 patients (54 eyes) | 12 months |
| Grabska-Liberek 20226 | Prospective interventional case series | Viscodilation/ trabeculotomy: OMNI Phacoemulsification + viscodilation/ trabeculotomy: OMNI + Phacoemulsification | 15 patients (17 eyes) | 12 months |
| Guedes 201968 | Longitudinal retrospective study | iStent, iStent inject | 73 eyes | 6 months |
| Guedes 202169 | Longitudinal retrospective study | iStent, iStent inject | 82 patients (82 eyes) | 24 months |
| Hirsch 202170 | Retrospective observational study | OMNI | 81 patients (81 eyes) | Mean (SD): 316 (63.9) days |
| Hooshmand 201971 | Prospective interventional case series | iStent, iStent inject | 148 patients (245 eyes) | 18 months |
| Hughes 202072 | Retrospective case series | Canaloplasty: Visco360 or OMNI Group 2 Canaloplasty + Phacoemulsification: Visco360 or OMNI System devices | 64 patients (89 eyes) | 18 months |
| Ibáñez-Muñoz 202073 | Retrospective, comparative study design | Xen | 68 patients (73 eyes) | 12 months |
| Jones 201922 | Prospective RCT | Hydrus | 331 eyes | 24 months |
| Khaimi 202126 | Retrospective case series | iTrack | 35 patients (45 eyes) | 36 months |
| Khan 201574 | Retrospective case series | iStent | 101 eyes | 12 months |
| Klabe 202117 | Retrospective study | OMNI | 27 patients (38 eyes) | 24 months |
| Klamann 201414 | Prospective study | SLT | 64 patients (64 eyes) | 3 months |
| Klamann 201575 | Retrospective cohort study | iStent inject | 35 patients (35 eyes) | 6 months |
| Konopińska 202021 | Prospective uncontrolled interventional case series | iStent | 72 patients | 24 months |
| Kozera 202123 | RCT | iStent | 57 patients (80 eyes) | Mean (range): 24.6 (24–36) months |
| Le 201976 | Retrospective, non-randomised, comparative study | iStent + phacoemulsification, KDB + phacoemulsification, KDB, Alcon Infiniti | 48 patients (77 eyes) | Minimum: 12 months iStent group, mean: 26.4 months KDB group, mean: 13.9 months |
| Lee 201977 | Retrospective comparative case series | KDB, iStent | 74 patients (102 eyes) 40 patients (58 eyes) |
6 months |
| Lee 202078 | Retrospective case series | iStent Hydrus |
190 patients (297 eyes) | 24 months |
| Maier 202079 | Retrospective cohort study | iStent inject | 66 patients (66 eyes) | 24 months |
| Ondrejka 201980 | Retrospective surgical case series | Visco360 Viscosurgical System | 71 patients (106 eyes) | Mean (range): 12 (9–15) months |
| Pahlitzsch 202181 | Retrospective cohort study | SLT, iStent inject | 342 patients | 3 years |
| Patel 201318 | Prospective interventional case series | iStent | 44 eyes | 6 months |
| Pérez-Torregrosa 201612 | Prospective non-randomised study | Xen | 18 patients (30 eyes) | 12 months |
| Pillunat 202182 | Prospective interventional cohort study | PreserFlo MicroShunt | 52 patients (52 eyes) | 6 months |
| Salby 202083 | Retrospective study | iStent inject | 75 patients (122 eyes) | 24 months |
| Salimi 202084 | Retrospective case series | iStent inject | 42 patients (62 eyes) | 12 months |
| Salimi 202185 | Longitudinal case series | iStent inject | 75 patients (124 eyes) | 3 years |
| Samuelson 201120 | RCT | iStent inject with cataract surgery | 240 eyes | 12 months |
| Samuelson 201919 | RCT | iStent inject | 505 eyes | 24 months |
| Schweitzer 202031 | Prospective interventional single-arm clinical trial | iStent, iStent inject | 47 eyes | 3 months |
| Seibold 201686 | Retrospective case series | iStent | 45 patients (64 eyes) | 12 months |
| Seixas 202087 | Longitudinal retrospective study | iStent inject | 49 patients (86 eyes) | 6 months |
| Shazly 201188 | Retrospective study | SLT | 40 patients (80 eyes) | 30 months |
| Toneatto 202289 | Retrospective, observational, consecutive design | OMNI | 73 patients (80 eyes) | 12 months |
| Ventura-Abreu 202152 | RCT | KDB | 43 eyes | 12 months |
| Vold 202190 | Retrospective, observational, stratified, consecutive study | OMNI | 48 patients (48 eyes) | Mean (SD): 335 (54.8) days |
| Weiner 202091 | Retrospective interventional case series | Trabeculectomy (Trabectome), iStent | 45 patients (90 eyes) | 30 months |
| Tan 201640 | Prospective, uncontrolled interventional case series | iStent | 41 patients | 3 years |
| Economic or humanistic outcomes | ||||
| Ahmed 2020b44 | Cost-effectiveness analysis | Hydrus | NA | NA |
| Ahmed 2020c47 | Cost-utility analysis | iStent inject | NA | NA |
| Dirani 201192 | Cost-effectiveness analysis | NA | NA | NA |
| Fea 202142 | Cost-utility analysis | iStent inject | NA | NA |
| Floriani 201627 | Cross-sectional observational study | NA | 3169 patients | NA (cross-sectional study) |
| Guedes 201638 | Cost-effectiveness analysis | NA | NA | NA |
| Igarashi 201941 | Cost-utility analysis | iStent inject | NA | NA |
| Kong 201429 | Prospective, hospital-based, cross-sectional study | NA | 500 patients | NA (cross-sectional study) |
| Lazcano-Gomez 201637 | Prospective survey | NA | 462 patients | 5 years |
| Lorenz 201336 | Non-interventional cross-sectional study | NA | 154 patients | NA (cross-sectional study) |
| Martínez-de-la-Casa 201949 | Budget impact analysis | Xen | 135 patients (in one year) | NA |
| Mudd 201843 | Cost-utility analysis | iStent inject | NA | NA |
| Nieland 202145 | Cost-effectiveness analysis | iStent inject | NA | NA |
| Patel 201946 | Cost-effectiveness analysis | Two iStents or one iStent Inject | NA | NA |
| Riva 201930 | Prospective cohort study | NA | 178 patients | 12 months |
| Shih 202139 | Retrospective cohort study | NA | 177,352 patients | 12 months |
| Skalicky 201232 | Cross-sectional study | NA | 124 patients | NA (cross-sectional study) |
| Sood 202148 | Cost-utility analysis | iStent inject, Hydrus | NA | NA |
| Teus 202150 | Cost-effectiveness analysis | iStent inject | NA | NA |
| Wolfram 201333 | Cross-sectional non-interventional study | NA | 154 patients | NA (cross-sectional study) |
| Yang 201634 | Cross-sectional survey | NA | 118 patients | NR (cross-sectional study) |
Note: Some studies reported clinical and economic/humanistic outcomes, hence have been grouped according to the primary outcome reported.
Abbreviations: IOL, intraocular lens; IOP, intraocular pressure; KDB, Kahook Dual Blade; NA, not applicable; NR, not reported; RCT, randomised controlled trial; SD, standard deviation; SLT, selective laser trabeculoplasty.